A retrospective study of clinical use of recombinant human erythropoietin for treatment in anemic dogs with canine monocytic ehrlichiosis from an animal hospital in Bangkok, Thailand

2008 ◽  
Vol 17 (4) ◽  
pp. 237-243 ◽  
Author(s):  
Sukullaya Assarasakorn ◽  
Morakot Kaewthamasorn ◽  
Nawin Manachai
Keyword(s):  
Retrospective Study ◽  
Recombinant Human Erythropoietin ◽  
Clinical Use ◽  
Human Erythropoietin ◽  
Canine Monocytic Ehrlichiosis

Evidence-based recommendations for the clinical use of recombinant human erythropoietin

1995 ◽  
Vol 26 (2) ◽  
pp. S1-S24 ◽  
Author(s):  
Norman Muirhead ◽  
Joanne Bargman ◽  
Ellen Burgess ◽  
Kailash K. Jindal ◽  
Adeera Levin ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Evidence Based ◽  
Clinical Use ◽  
Human Erythropoietin

scholarly journals Clinical Indications of Recombinant Human Erythropoietin in a Single Center: A 10-Year Retrospective Study

2020 ◽  
Vol 11 ◽  
Author(s):  
Xiao-Zhen Guan ◽  
Lei-Li Wang ◽  
Xue Pan ◽  
Li Liu ◽  
Xiao-Lin Sun ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Recombinant Human Erythropoietin ◽  
Single Center ◽  
Human Erythropoietin ◽  
Clinical Indications

Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study

2014 ◽  
Vol 93 (8) ◽  
pp. 1413-1420 ◽  
Author(s):  
Caterina Tatarelli ◽  
Anna Lina Piccioni ◽  
Luca Maurillo ◽  
Virginia Naso ◽  
Roberta Battistini ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Elderly Patients ◽  
Myelodysplastic Syndromes ◽  
Recombinant Human Erythropoietin ◽  
Very Elderly ◽  
Human Erythropoietin

Role of recombinant human erythropoietin in the treatment of cancer-related anaemia

Oncoreview ◽  
2017 ◽  
Vol 7 (2) ◽  
Author(s):  
Tomasz Jankowski ◽  
Tomasz Kubiatowski
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Human Erythropoietin

Correlation Between Recombinant Human Erythropoietin Dose and Inflammatory Status in Dialysed Patients

2017 ◽  
Vol 68 (2) ◽  
pp. 354-357 ◽  
Author(s):  
Andrei Niculae ◽  
Cristiana David ◽  
Razvan Florin Ion Dragomirescu ◽  
Ileana Peride ◽  
Flavia Liliana Turcu ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Recombinant Human Erythropoietin ◽  
Best Practice ◽  
Daily Practice ◽  
Therapeutic Benefit ◽  
Chronic Dialysis ◽  
Dialysis Patients ◽  
Protein Levels ◽  
Human Erythropoietin ◽  
Inflammatory Status

Once recombinant human erythropoietin (r-HuEPO) was introduced in daily practice, huge steps were made in combating the adverse effects induced by anemia in chronic kidney disease population. Still, r-HuEPO resistance and the doses ensuring the maximum therapeutic benefit remain matters of debate. The aim of our study was to assess the correlation between the presence and the degree of inflammation and the r-HuEPO requirements in chronic dialysis patients. We conducted a 2 years prospective study on 146 patients undergoing chronic dialysis treated with r-HuEPO. Based on their average CRP (C-reactive protein) levels, obtained from repeated samplings at 3 months interval, 3 groups were formed; we noted in each group the average values of r-HuEPO prescribed to achieve the optimum hemoglobin levels according to the dialysis best practice guidelines and all the adverse effects of the therapy. A direct correlation was observed between CRP levels and r-HuEPO requirements in the first 2 groups of patients (CRP under 6 mg/L and CRP values 6-20 mg/L), with significant increase in r-HuEPO doses between groups (p [ 0.001); the third group, CRP values over 20 mg/dL, showed a minor, insignificant increase in average r-HuEPO doses compared to mild inflammation group (p = 0.199) and more adverse effects of the therapy (p [ 0.05). Inflammation is an important determinant of anemia in chronic dialysis patients and can induce an increase in the doses of r-HuEPO. However, prescribing excessive r-HuEPO doses is not the answer in severe inflammatory status, due to lack of response and possible adverse effects.

Sign in / Sign up

Export Citation Format

Share Document